PM-8003

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NamePM-8003

Drug Alias NamePM8003

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersVascular endothelial growth factor inhibitorsTransforming growth factor beta inhibitors

TargetsProgrammed death-ligand 1Vascular endothelial growth factorTransforming growth factor beta

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator Companies +[1] N/A

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active Companies +[1] N/A

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A